Skip to main content

Chronic Inflammatory Demyelinating Polyneuropathy

Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
NCT03779828 | PHASE 1 | OBSERVATIONAL

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course. Diagnosis is based on clinical presentation and electrophysiological findings in accordance with the EFNS/PNS consensus guidelines. IVIg is the first line treatment witch has been shown to be effective in several placebo-controlled trials. Once IVIg therapy produces a response and is well tolerated, some patients are able to continue their treatment in the home setting. The HOME LINK system offers an integrated, global solution based on telemonitoring technology providing continuous, remote monitoring of Privigen® infusions administered at home.

Trial Information
10 Sites
11 Participants
Recruiting
65 Years to 85 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Hpital Pellegrin, Bordeaux University Hospital (CHU)
Bordeaux,France
Hpital Henri Mondor APHP
Créteil,France
Hpital Roger Salengro CHRU
Lille,France
Hpital Pierre Wertheimer HCL
Lyon,France
Hpital La Timone APHM
Marseille,France
Hpital Gui de Chauliac Montpellier University Hospital (CHU)
Montpellier,France
Hpital Pasteur Nice University Hospital (CHU)
Nice,France
Hpital La PitiSalptrire APHP
Paris,France
Hpital Lariboisire APHP
Paris,France
Hpital Nord Saint Etienne University Hospital (CHU)
Saint Etienne,France

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov